Thought Leadership
 
Email Page
Can The FDA Salvage Interchangeable Follow-On Biologics?
November 19, 2019
Ted Mathias, Stacie Ropka, and Michelle Divelbiss*
BioProcess Online / Biosimilar Development

BioProcess Online and Biosimilar Development published "Can The FDA Salvage Interchangeable Follow-On Biologics?", an article written by Axinn partners Ted Mathias and Stacie Ropka and associate Michelle Divelbiss*.

*Not yet admitted to the Washington, DC Bar.